IceCure's ProSense Sales Soar 84% in North America, Global Revenue Up 26% in Q1
ICCM is trading near its 52-week low of $0.23 (1.3% above the low).
Summary
IceCure Medical reported strong first-quarter 2026 financial results, with global revenue increasing 26% and North American sales for its ProSense® system soaring 84% year-over-year. This significant growth, particularly in North America, is attributed to increased adoption following FDA clearance and an expanding reimbursement framework, leading to a 46% increase in active customer accounts. For a micro-cap company trading near its 52-week low and recently facing a class action lawsuit and a "going concern" warning, these positive sales figures are a critical development. Traders will be watching if this commercial momentum can be sustained and if it helps to alleviate the company's broader financial and legal challenges. The company plans to expand its U.S. sales footprint to eight regions this year.
At the time of this announcement, ICCM was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.5M. The 52-week trading range was $0.23 to $1.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.